[
  {
    "ts": null,
    "headline": "Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has dealt with some hurdles in the past, but it has secured several key new drug approvals in recent years. One of the most notable is Reblozyl, a treatment for anemia in individuals with beta-thalassemia, a […]",
    "url": "https://finnhub.io/api/news?id=4b2969a44ff6cfebc2bcc3f55ffc8468efb2ffac064a26cf94b428bd4f1f67bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752887234,
      "headline": "Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025",
      "id": 136012024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has dealt with some hurdles in the past, but it has secured several key new drug approvals in recent years. One of the most notable is Reblozyl, a treatment for anemia in individuals with beta-thalassemia, a […]",
      "url": "https://finnhub.io/api/news?id=4b2969a44ff6cfebc2bcc3f55ffc8468efb2ffac064a26cf94b428bd4f1f67bb"
    }
  }
]